Neprilysin Inhibition — A Novel Therapy for Heart Failure

Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial

(2014) Pardeep S. Jhund et al.   EUROPEAN JOURNAL OF HEART FAILURE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renin–Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation

(2013) Thomas G. von Lueder et al.   Circulation-Heart Failure

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

(2010) Luis Miguel Ruilope et al.   LANCET

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

(2010) Karl Swedberg et al.   LANCET

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events

(2009) Arthur J. Moss et al.   NEW ENGLAND JOURNAL OF MEDICINE